Cancer Genetics Inc. (NASDAQ:CGIX)’s share price rose 2.5% on Thursday . The company traded as high as $2.16 and last traded at $2.08, with a volume of 106,428 shares. The stock had previously closed at $2.03.

Separately, Zacks Investment Research raised Cancer Genetics from a “hold” rating to a “buy” rating and set a $2.25 price target for the company in a report on Thursday, July 28th.

The company’s 50-day moving average is $2.14 and its 200-day moving average is $2.31. The firm’s market capitalization is $33.05 million.

Cancer Genetics (NASDAQ:CGIX) last posted its earnings results on Wednesday, August 10th. The company reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.33) by $0.05. During the same quarter in the prior year, the business earned ($0.51) earnings per share. The business earned $7 million during the quarter, compared to analyst estimates of $6.50 million. The firm’s revenue was up 67.3% compared to the same quarter last year. Equities research analysts predict that Cancer Genetics Inc. will post ($1.19) EPS for the current fiscal year.

In other Cancer Genetics news, Director John Pappajohn bought 45,000 shares of the stock in a transaction that occurred on Tuesday, August 16th. The shares were purchased at an average cost of $2.29 per share, for a total transaction of $103,050.00. Following the transaction, the director now directly owns 2,287,109 shares in the company, valued at $5,237,479.61. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Cancer Genetics, Inc is engaged in the field of personalized medicine, enabling precision medicine in the field of oncology through its diagnostic products and services, and molecular markers. The Company develops, commercializes and provides molecular- and biomarker-based tests and services that enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor and inform cancer treatment, and enable biopharmaceutical companies engaged in oncology trials to select candidate populations and manage adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.